Overview

Nivolumab in Relapsed Pediatric Solid Tumors

Status:
Unknown status

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

patients with progressive/relapsed solid tumors who failed first line therapy , will be treated biweekly with the anti PD1- Nivolumab. at least one month after treatment initiation low dose cyclophosphamide will be started . patients on trial will submit tissue and blood tests for whole exome an immune genomic signature. patients will also undergo repeated immunophenotype as part of follow up.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hadassah Medical Organization

Treatments:

Antibodies, Monoclonal
Cyclophosphamide
Nivolumab